A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-08. Anything still debated is marked as such rather than presented as settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Strontium is named after the Scottish village of Strontian (Scottish Gaelic: Sròn an t-Sìthein), where it was discovered in the ores of the lead mines. In 1790, Adair Crawford, a physician engaged in the preparation of barium, and his colleague William Cruickshank, recognised that the Strontian ores exhibited properties that differed from those in other "heavy spars" sources. This allowed Crawford to conclude on page 355 "... it is probable indeed, that the scotch mineral is a new species of earth which has not hitherto been sufficiently examined." The physician and mineral collector Friedrich Gabriel Sulzer analysed together with Johann Friedrich Blumenbach the mineral from Strontian and named it strontianite. He also came to the conclusion that it was distinct from the witherite and contained a new earth (neue Grunderde). In 1793 Thomas Charles Hope, a professor of chemistry at the University of Glasgow studied the mineral and proposed the name strontites. He confirmed the earlier work of Crawford and recounted: "... Considering it a peculiar earth I thought it necessary to give it an name. I have called it Strontites, from the place it was found; a mode of derivation in my opinion, fully as proper as any quality it may possess, which is the present fashion." The element was eventually isolated by Sir Humphry Davy in 1808 by the electrolysis of a mixture containing strontium chloride and mercuric oxide, and announced by him in a lecture to the Royal Society on 30 June 1808. In keeping with the naming of the other alkaline earths, he changed the name to strontium.
== History == Spontaneous vertebral artery dissection was described in the 1970s. Prior to this, there had been isolated case reports about carotid dissection. In 1971, C. Miller Fisher, a Canadian neurologist and stroke physician working at Massachusetts General Hospital, first noted the "string sign" abnormality in carotid arteries on cerebral angiograms of stroke patients, and subsequently discovered that the same abnormality could occur in the vertebral arteries. He reported the discovery in a paper in 1978.
=== As an invasive species === Japanese honeysuckle has become naturalized in Argentina, Australia, Brazil, Mexico, New Zealand, and much of the United States, including Hawaii, as well as a number of Pacific and Caribbean islands. It is classified as a noxious weed in 46 states, being prohibited to be bought and sold in Connecticut, Illinois, Massachusetts, and Vermont, and banned in Indiana and New Hampshire. It is on the New Hampshire invasive species list. Lonicera japonica was initially brought to the U.S. from Japan in the early 1800s as an ornamental plant. It is still deliberately planted in the U.S. for reasons such as erosion control or forage for deer, but has become invasive in many areas. It prefers to invade areas that have been disturbed, such as roadsides or floodplains. It will generally only invade forests when the canopy has been opened by logging or fallen trees, as it grows less vigorously in the shade. Once it has invaded an area, Lonicera japonica grows rapidly and outcompetes native plants for sunlight and nutrients. It proliferates using both sexual and vegetative reproduction, producing seeds that are spread by animals and expanding locally via rhizomes. Eventually, it will form a dense thicket which prevents other plant species from germinating in that area. Due to its suppression of germination in the understory, Lonicera japonica also prevents the regeneration of trees.
=== Distribution === From 1977 to 1981, SOLAR was distributed by RCA Records, which had also distributed the Soul Train Records label during its two-year run. Griffey formed a second label, Constellation Records (no relation to the Chicago-based indie label founded by Ewart Abner) in 1981, which focused on more contemporary and top forty-geared acts to Griffey's more traditionally "urban" establishment (including Jon Gibson and Klymaxx). Upon its formation, Constellation was distributed through Elektra/Asylum Records, making it only natural for the main SOLAR label to jump ship to Elektra for distribution when it left RCA. In the meantime, the Constellation label moved to MCA Records for distribution in 1984. Shortly thereafter, Griffey decided to abandon contemporary music to focus all of his attention on running SOLAR, and retaining its sonic theme. Subsequently, MCA bought the Constellation imprint and absorbed its artists, including Klymaxx, which had been its biggest act. SOLAR's relationship with Elektra lasted until 1986. After the Elektra distribution deal expired, SOLAR briefly took up distribution with Capitol Records until 1989, at which time it signed a new distribution deal with Epic Records, which oversaw what would ultimately become its twilight years. In the early 1990s, the label released its last recordings- 1991's Now by Richie Havens and Times 3's eponymous debut album, the soundtrack to the 1992 film Deep Cover, 3rd Avenue's 1992 debut album Let's Talk About Love, and 1993 The Deele album An Invitation To Love.
Another aspect of QD toxicity is that there are, in vivo, size-dependent intracellular pathways that concentrate these particles in cellular organelles that are inaccessible by metal ions, which may result in unique patterns of cytotoxicity compared to their constituent metal ions. The reports of QD localization in the cell nucleus present additional modes of toxicity because they may induce DNA mutation, which in turn will propagate through future generation of cells, causing diseases. Although concentration of QDs in certain organelles have been reported in in vivo studies using animal models, no alterations in animal behavior, weight, hematological markers, or organ damage has been found through either histological or biochemical analysis. These findings have led scientists to believe that intracellular dose is the most important determining factor for QD toxicity. Therefore, factors determining the QD endocytosis that determine the effective intracellular concentration, such as QD size, shape, and surface chemistry determine their toxicity. Excretion of QDs through urine in animal models also have demonstrated via injecting radio-labeled ZnS-capped CdSe QDs where the ligand shell was labeled with 99mTc. Though multiple other studies have concluded retention of QDs in cellular levels, exocytosis of QDs is still poorly studied in the literature. While significant research efforts have broadened the understanding of toxicity of QDs, there are large discrepancies in the literature, and questions still remain to be answered.
Sources: en.wikipedia.org
== General bibliography == Albertini, Luigi (2005). The Origins of the War of 1914. New York: Enigma Books. Murad, Anatol (1968). Franz Joseph I of Austria and his Empire. Twayne Publishers. ISBN 978-0-8290-0172-3. Palmer, Alan (1994). Twilight of the Habsburgs: The Life and Times of Emperor Francis Joseph. Atlantic Monthly Press. ISBN 978-0-8021-1560-7.
NGF (for "Nerve Growth Factor") BDNF (for "Brain Derived Neurotrophic Factor") NT-4 (for "Neurotrophin-4") While TrkB mediates the effects of BDNF, NT-4, and NT-3, TrkA binds and is activated by NGF, and TrkC binds and is activated only by NT-3.
=== Economics === In the United States, the 800 mcg tablet was 6.75 times more expensive as of 2020 than the lozenge. As of 2023, the average cost for an injectable fentanyl solution (50 mcg/mL) is around US$17 for a supply of 20 milliliters, depending on the pharmacy. In a 2020 report by the Australian Institute of Criminology, a 100-microgram transdermal patch was valued from between AU$75 and AU$450 on illicit markets. Furthermore, in another 2020 study, the average price per gram of non-pharmaceutical fentanyl on various cryptomarkets was US$1,470.40 for offerings of less than five grams; the average for offers over five grams was US$139.50. In addition, on DreamMarket furanfentanyl (Fu-F), the most common analog on said market, the average price per gram was US$243.10 for retail listings and US$26.50 per gram for wholesale listings.
Co-translational O-GlcNAc has been identified on Sp1 and Nup62. This modification suppresses co-translational ubiquitination and thus protects nascent polypeptides from proteasomal degradation. Similar protective effects of O-GlcNAc on full-length Sp1 have been observed. It is unknown if this pattern is universal or only applicable to specific proteins. Protein phosphorylation is often used as a mark for subsequent degradation. Tumor suppressor protein p53 is targeted for proteasomal degradation via COP9 signalosome-mediated phosphorylation of T155. O-GlcNAcylation of p53 S149 has been associated with decreased T155 phosphorylation and protection of p53 from degradation. β-catenin O-GlcNAcylation competes with T41 phosphorylation, which signals β-catenin for degradation, stabilizing the protein. O-GlcNAcylation of the Rpt2 ATPase subunit of the 26S proteasome has been shown to inhibit proteasome activity. Testing various peptide sequences revealed that this modification slows proteasomal degradation of hydrophobic peptides, degradation of hydrophilic peptides does not appear to be affected. This modification has been shown to suppress other pathways that activate the proteasome such as Rpt6 phosphorylation by cAMP-dependent protein kinase. OGA-S localizes to lipid droplets and has been proposed to locally activate the proteasome to promote remodeling of lipid droplet surface proteins.
Sources: en.wikipedia.org
==== United States ==== In the United States, immediate-release injectable nalmefene was approved in 1995, as an antidote for opioid overdose. It was sold under the brand name Revex. The product was discontinued by its manufacturer around 2008. A generic version was approved for medical use in the United States in February 2022. In May 2023, the Food and Drug Administration (FDA) approved a nalmefene hydrochloride nasal spray, under the brand name Opvee, for the emergency treatment of opioid overdose in people aged twelve years of age and older. In August 2024, the FDA approved a nalmefene hydrochloride auto-injector (Zurnai) for the emergency treatment of known or suspected opioid overdose in people aged twelve years of age and older. The FDA granted the application for the nalmefene hydrochloride auto-injector fast track and priority review designations. The FDA granted approval of Zurnai to Purdue Pharma L.P. As of 2012, nalmefene in pill form, used for the treatment of alcohol dependence and other addictive behaviors, is not available in the United States.
This indicates that all the protons have been removed. When this is so, the solution is not buffered and the pH rises steeply on addition of a small amount of strong base. However, the pH does not continue to rise indefinitely. A new buffer region begins at about pH 11 (pKw − 3), which is where self-ionization of water becomes important. It is very difficult to measure pH values of less than two in aqueous solution with a glass electrode, because the Nernst equation breaks down at such low pH values. To determine pK values of less than about 2 or more than about 11 spectrophotometric or NMR measurements may be used instead of, or combined with, pH measurements. When the glass electrode cannot be employed, as with non-aqueous solutions, spectrophotometric methods are frequently used. These may involve absorbance or fluorescence measurements. In both cases the measured quantity is assumed to be proportional to the sum of contributions from each photo-active species; with absorbance measurements the Beer–Lambert law is assumed to apply. Isothermal titration calorimetry (ITC) may be used to determine both a pK value and the corresponding standard enthalpy for acid dissociation. Software to perform the calculations is supplied by the instrument manufacturers for simple systems. Aqueous solutions with normal water cannot be used for 1H NMR measurements but heavy water, D2O, must be used instead. 13C NMR data, however, can be used with normal water and 1H NMR spectra can be used with non-aqueous media.
More recent data has not confirmed this association: it is thought that the disease itself is linked with a slightly higher background risk of malignancy. Ongoing data analysis on large patient populations continues in this area.
Industrial nitrogen fixation by the Haber process is mostly used as fertiliser, although excess nitrogen–bearing waste, when leached, leads to eutrophication of freshwater and the creation of marine dead zones, as nitrogen-driven bacterial growth depletes water oxygen to the point that all higher organisms die. Furthermore, nitrous oxide, which is produced during denitrification, attacks the atmospheric ozone layer. Many saltwater fish manufacture large amounts of trimethylamine oxide to protect them from the high osmotic effects of their environment; conversion of this compound to dimethylamine is responsible for the early odour in unfresh saltwater fish. In animals, free radical nitric oxide (derived from an amino acid), serves as an important regulatory molecule for circulation. Nitric oxide's rapid reaction with water in animals results in the production of its metabolite nitrite. Animal metabolism of nitrogen in proteins, in general, results in the excretion of urea, while animal metabolism of nucleic acids results in the excretion of urea and uric acid. The characteristic odour of animal flesh decay is caused by the creation of long-chain, nitrogen-containing amines, such as putrescine and cadaverine, which are breakdown products of the amino acids ornithine and lysine, respectively, in decaying proteins.
=== Reduction === Like esters, most carboxylic acids can be reduced to alcohols by hydrogenation, or using hydride transferring agents such as lithium aluminium hydride. Strong alkyl transferring agents, such as organolithium compounds but not Grignard reagents, will reduce carboxylic acids to ketones along with transfer of the alkyl group. The Vilsmaier reagent (N,N-Dimethyl(chloromethylene)ammonium chloride; [ClHC=N+(CH3)2]Cl−) is a highly chemoselective agent for carboxylic acid reduction. It selectively activates the carboxylic acid to give the carboxymethyleneammonium salt, which can be reduced by a mild reductant like lithium tris(t-butoxy)aluminum hydride to afford an aldehyde in a one pot procedure. This procedure is known to tolerate reactive carbonyl functionalities such as ketone as well as moderately reactive ester, olefin, nitrile, and halide moieties.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.